can008

mAbexperimental

Clinical trial activity

3 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Aug 1, 2016 (NCT02853565)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Also known as

  • can008

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05447195Phase 2Oct 10, 2021CANbridge Life Sciences Ltd., Capital Medical University
NCT03746288Phase 2Nov 20, 2018CANbridge Life Sciences Ltd.
NCT02853565Phase 1Aug 1, 2016CANbridge Life Sciences Ltd.
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
CANbridge Life Sciences Ltd.For profit3322016
Capital Medical UniversityAcademic/Hospital1012021
2 organizations
Page 1 / 1